Table 2.
Laboratory findings of patients infected with 2019-nCoV on admission to hospital
| All patients (n=41) | ICU care (n=13) | No ICU care (n=28) | p value | ||
|---|---|---|---|---|---|
| White blood cell count, × 109/L | 6·2 (4·1–10·5) | 11·3 (5·8–12·1) | 5·7 (3·1–7·6) | 0·011 | |
| <4 | 10/40 (25%) | 1/13 (8%) | 9/27 (33%) | 0·041 | |
| 4–10 | 18/40 (45%) | 5/13 (38%) | 13/27 (48%) | .. | |
| >10 | 12/40 (30%) | 7/13 (54%) | 5/27 (19%) | .. | |
| Neutrophil count, × 109/L | 5·0 (3·3–8·9) | 10·6 (5·0–11·8) | 4·4 (2·0–6·1) | 0·00069 | |
| Lymphocyte count, × 109/L | 0·8 (0·6–1·1) | 0·4 (0·2–0·8) | 1·0 (0·7–1·1) | 0·0041 | |
| <1·0 | 26/41 (63%) | 11/13 (85%) | 15/28 (54%) | 0·045 | |
| ≥1·0 | 15/41 (37%) | 2/13 (15%) | 13/28 (46%) | .. | |
| Haemoglobin, g/L | 126·0 (118·0–140·0) | 122·0 (111·0–128·0) | 130·5 (120·0–140·0) | 0·20 | |
| Platelet count, × 109/L | 164·5 (131·5–263·0) | 196·0 (165·0–263·0) | 149·0 (131·0–263·0) | 0·45 | |
| <100 | 2/40 (5%) | 1/13 (8%) | 1/27 (4%) | 0·45 | |
| ≥100 | 38/40 (95%) | 12/13 (92%) | 26/27 (96%) | .. | |
| Prothrombin time, s | 11·1 (10·1–12·4) | 12·2 (11·2–13·4) | 10·7 (9·8–12·1) | 0·012 | |
| Activated partial thromboplastin time, s | 27·0 (24·2–34·1) | 26·2 (22·5–33·9) | 27·7 (24·8–34·1) | 0·57 | |
| D-dimer, mg/L | 0·5 (0·3–1·3) | 2·4 (0·6–14·4) | 0·5 (0·3–0·8) | 0·0042 | |
| Albumin, g/L | 31·4 (28·9–36·0) | 27·9 (26·3–30·9) | 34·7 (30·2–36·5) | 0·00066 | |
| Alanine aminotransferase, U/L | 32·0 (21·0–50·0) | 49·0 (29·0–115·0) | 27·0 (19·5–40·0) | 0·038 | |
| Aspartate aminotransferase, U/L | 34·0 (26·0–48·0) | 44·0 (30·0–70·0) | 34·0 (24·0–40·5) | 0·10 | |
| ≤40 | 26/41 (63%) | 5/13 (38%) | 21/28 (75%) | 0·025 | |
| >40 | 15/41 (37%) | 8/13 (62%) | 7/28 (25%) | .. | |
| Total bilirubin, mmol/L | 11·7 (9·5–13·9) | 14·0 (11·9–32·9) | 10·8 (9·4–12·3) | 0·011 | |
| Potassium, mmol/L | 4·2 (3·8–4·8) | 4·6 (4·0–5·0) | 4·1 (3·8–4·6) | 0·27 | |
| Sodium, mmol/L | 139·0 (137·0–140·0) | 138·0 (137·0–139·0) | 139·0 (137·5–140·5) | 0·26 | |
| Creatinine, μmol/L | 74·2 (57·5–85·7) | 79·0 (53·1–92·7) | 73·3 (57·5–84·7) | 0·84 | |
| ≤133 | 37/41 (90%) | 11/13 (85%) | 26/28 (93%) | 0·42 | |
| >133 | 4/41 (10%) | 2/13 (15%) | 2/28 (7%) | .. | |
| Creatine kinase, U/L | 132·5 (62·0–219·0) | 132·0 (82·0–493·0) | 133·0 (61·0–189·0) | 0·31 | |
| ≤185 | 27/40 (68%) | 7/13 (54%) | 20/27 (74%) | 0·21 | |
| >185 | 13/40 (33%) | 6/13 (46%) | 7/27 (26%) | .. | |
| Lactate dehydrogenase, U/L | 286·0 (242·0–408·0) | 400·0 (323·0–578·0) | 281·0 (233·0–357·0) | 0·0044 | |
| ≤245 | 11/40 (28%) | 1/13 (8%) | 10/27 (37%) | 0·036 | |
| >245 | 29/40 (73%) | 12/13 (92%) | 17/27 (63%) | .. | |
| Hypersensitive troponin I, pg/mL | 3·4 (1·1–9·1) | 3·3 (3·0–163·0) | 3·5 (0·7–5·4) | 0·075 | |
| >28 (99th percentile) | 5/41 (12%) | 4/13 (31%) | 1/28 (4%) | 0·017 | |
| Procalcitonin, ng/mL | 0·1 (0·1–0·1) | 0·1 (0·1–0·4) | 0·1 (0·1–0·1) | 0·031 | |
| <0·1 | 27/39 (69%) | 6/12 (50%) | 21/27 (78%) | 0·029 | |
| ≥0·1 to <0·25 | 7/39 (18%) | 3/12 (25%) | 4/27 (15%) | .. | |
| ≥0·25 to <0·5 | 2/39 (5%) | 0/12 | 2/27 (7%) | .. | |
| ≥0·5 | 3/39 (8%) | 3/12 (25%)* | 0/27 | .. | |
| Bilateral involvement of chest radiographs | 40/41 (98%) | 13/13 (100%) | 27/28 (96%) | 0·68 | |
| Cycle threshold of respiratory tract | 32·2 (31·0–34·5) | 31·1 (30·0–33·5) | 32·2 (31·1–34·7) | 0·39 | |
Data are median (IQR) or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and no ICU care are from χ2, Fisher's exact test, or Mann-Whitney U test. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit.
*
Complicated typical secondary infection during the first hospitalisation.